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In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient
clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers
have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition
receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and
compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from
the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis
based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous can-
cer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident
cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were
significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not
diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed
cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investi-
gated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly
associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.
Cancer is the leading cause of death in Denmark. To reduce
diagnostic delay and improve survival, between 2007 and 2012,
the Danish Health Authority introduced standardized fast-track
outpatient cancer pathways. A pathway was designed for patients
with serious nonspeciﬁc symptoms and signs of disease that
could be cancer (NSSC) and patients with metastasis without a
known primary tumor or organ-speciﬁc manifestation. These
patients undergo an accelerated pathway of cancer diagnostics at
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Abbreviations: AUC: area under the curve; CI: confidence interval; CRP: C-reactive protein; DOC: diagnostic outpatient clinic; ESR:
erythrocyte sedimentation rate; IQR: interquartile range; MBL: mannose-binding lectin; NAD: no abnormality detected; NMD:
nonmalignant disease; NPV: negative predictive value; NSSC: nonspecific symptoms and signs of cancer; PPV: positive predictive value;
PRR: pattern recognition receptor; ROC: receiver operating characteristics; SD: standard deviation; suPAR: soluble urokinase plasminogen
activator receptor; WBC: white blood cell.
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the diagnostic outpatient clinics (DOCs). The prevalence of can-
cer diagnosed at Danish DOCs is 16–20%.1–3 The remaining
patients are found to have a wide range of nonmalignant dis-
eases, but 25–50% of the patients leave the DOCs without a spe-
ciﬁc diagnosis.1,2
Screening and diagnosis is challenging as patients referred
to the DOCs form a heterogeneous group. Possible advances
in the diagnostic strategy must be studied to improve
accuracy and safety when examining patients suspected of
having serious disease.
Patients are characterized by different nonspeciﬁc com-
plaints, such as weight loss, fatigue, diffuse abdominal or bone
pain, anemia or an increase in drug usage or more frequent
contacts with the health care system.1 The initial diagnostic
process at the DOC includes a focused medical history, a physi-
cal examination, application of an expanded panel of biochemi-
cal analyses and, if malignancy remains suspected, imaging is
performed.3
Research has recently reported various immunological and
inﬂammatory serum biomarkers associated with different types
of cancer that could constitute new diagnostic or prognostic
markers in the development of cancer and prognosis.4–6
Fluid-phase pattern recognition receptors (PRRs) of the
innate immune system, including pentraxin-3, mannose-bind-
ing lectin (MBL), ﬁcolin-1, ﬁcolin-2 and ﬁcolin-3, recognize
pathogens and modiﬁed self-molecules and have been found
to be associated with cancer.7–17 Another novel biomarker in
this setting is the soluble urokinase plasminogen activator
receptor (suPAR) which reﬂects inﬂammatory activity. suPAR
is the soluble form of uPAR which, in cancer, is expressed on
cancer cells and stromal cells.18–20 Several studies show an
association between suPAR and the presence and prognosis
of different types of cancer21–27 as well as an increased risk
of developing lung cancer in the general population.28
Little is known as to how these biomarkers perform in a
heterogeneous group of patients with diffuse and nonspeciﬁc
symptoms. Therefore, we evaluated these novel biomarkers
and compared their diagnostic ability to that of classical bio-
markers for diagnosing cancer in patients with NSSC.
Materials and Methods
Study design and patient inclusion
The current study of biomarkers in the DOC was conducted
as part of a study evaluating two different diagnostic imaging
modalities, 18F-FDG-PET/CT vs. conventional CT of the tho-
rax and abdomen.3
Patients were prospectively included from the DOC,
Department of Infectious Diseases, Copenhagen University
Hospital Hvidovre between August 14, 2013, and April 30,
2014. Patients were referred from their general practitioner, a
medical specialist or other hospital departments. The criteria
for referral to the DOC were suspicion of serious illness or
suspicion of metastasis without a known primary tumor,
based on one or more of the following symptoms present
that do not ﬁt into any of the organ-speciﬁc cancer diagnos-
tic programs: general malaise, severe tiredness, unintentional
weight loss, fever of unknown cause, uncharacteristic abdomi-
nal pain for >4 weeks, anemia, abnormal laboratory tests (e.g.,
elevated alkaline phosphatase levels, erythrocyte sedimentation
rate (ESR), calcium etc.), diffuse bone pain, pathologically
enlarged lymph nodes, marked increase in drug usage or
increasing health service seeking behavior.
Inclusion criteria for the study were i) age 18 years,
ii) referred to the DOC due to nonspeciﬁc symptoms or signs
of cancer and iii) signed informed consent. Exclusion criteria
were i) pregnancy, including risk of pregnancy and lactation,
ii) alcohol or drug abuse hampering the ability to adhere to the
protocol, iii) claustrophobia, iv) bodyweight above 150 kg, v)
contraindications to CT due to allergy to contrast or impaired
renal function deﬁned as P-creatinine level >0.120 mmol/L or vi)
deemed unﬁt due to performance status.
Randomization and clinical evaluation was performed as pre-
viously described.3 Brieﬂy, at the ﬁrst visit to the DOC, patients
were randomized 1:1 to be scanned with either conventional CT
or 18F-FDG-PET/CT. The randomization was based on a
computer-generated list (GraphPad Software, Inc., La Jolla, CA)
and was performed by a study nurse blinded to the patient’s
medical history, prior to any laboratory testing. Experienced
certiﬁed radiologists and nuclear medicine physicians analyzed
the CT or 18F-FDG-PET/CT data and discussed the results with
the clinicians. Furthermore, patients went through a physical
examination including evaluation of biochemistry. The com-
bined results from scans, blood work and physical examination
provided the basis for the diagnostic decisions made by the
DOC physicians at a multidisciplinary conference with the
participation of specialist physicians from the following medical
specialties: endocrinology, gastroenterology, nuclear medicine,
radiology and infectious diseases. A preliminary tentative
What’s new?
In Denmark, patients with serious non-specific symptoms and signs of cancer are referred to an accelerated cancer diagnostic
program. But screening and diagnosis is challenging as patients form a heterogeneous group. Possible advances in the diag-
nostic strategy must be studied to improve accuracy and safety. This study found that the novel inflammatory biomarker
suPAR and the routinely evaluated inflammatory biomarker CRP were independently associated with incident cancer diagno-
ses, while the innate immune markers, pentraxin-3, mannose-binding lectin and ficolin-1-3, were not. Addition of suPAR to
the existing blood samples may improve diagnosis and prognostication of cancer in this heterogeneous patient group.
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diagnosis was given here, and a ﬁnal referral diagnosis was given
when the full investigational program for disease at the DOC
was complete. If a malignant diagnosis was established, the
patients were referred to further treatment.
Patients were followed for 12 months after ﬁnishing their
investigations in the DOC by reviewing the electronic medi-
cal records, for conﬁrmation of malignant diagnoses based
on pathology results from biopsies etc.
Measurements
Weight loss and previous cancer diagnoses were self-reported
measures, registered in the electronic medical records at the
ﬁrst visit to the DOC.
Albumin, CRP, hemoglobin, lactate dehydrogenase, ESR
and white blood cell count were analyzed as part of the rou-
tine evaluation at the Department of Clinical Biochemistry,
Copenhagen University Hospital Hvidovre.
Plasma suPAR levels were analyzed with the suPARnostic
AUTO Flex ELISA (ViroGates A/S, Birkerød, Denmark) on
an automated Siemens BEP2000 platform at the Department
of Clinical Biochemistry according to the manufacturer’s
instructions.
Plasma concentrations of ﬁcolin-1, ﬁcolin-2, ﬁcolin-3, pen-
traxin-3 and MBL were determined by sandwich ELISAs using
speciﬁc in house-produced monoclonal antibodies as previ-
ously described.29–33 All assays were optimized for automated
analysis in 384-well format on Biomek FX (Beckman Coulter,
Fullerton, CA).
The Charlson comorbidity index (Charlson score) was
assessed at the ﬁrst consultation at the DOC by reviewing the
patient’s medical record.
Outcomes and covariates
The primary outcome was any incident cancer diagnoses
within 1 year.
Multivariate analyses were adjusted for age and sex, and
furthermore, as CRP is a widely used marker of inﬂammation
in the clinic, we included CRP in the adjusted analyses.
Statistical analysis
Continuous variables are presented as mean and standard
deviation (SD) or median and interquartile range (IQR).
Categorical variables are presented as number and percentage.
Differences between groups were tested with t-test, Fisher’s
exact test or the Wilcoxon two-sample test where appropriate.
Associations were analyzed by multiple logistic regression.
For these analyses, weight loss was categorized in groups per
5 kg weight loss, hemoglobin was log(1.1)-transformed and albu-
min, lactate dehydrogenase, CRP, ESR, suPAR, ﬁcolin-1, ﬁcolin-
2, ﬁcolin-3, MBL and pentraxin-3 were log(2)-transformed.
Kendall’s Tau-b correlation coefﬁcient was reported for
pairwise correlation analyses for CRP, ESR and suPAR.
Biomarker discriminative abilities with regards to cancer
were evaluated with area under the curve (AUC) for receiver
operating characteristic (ROC) curves and logistic regression
analyses, calculating sensitivity, speciﬁcity, negative predictive
value (NPV) and positive predictive value (PPV) for adjusted
models. The Youden’s index was used as cutoff value.34
SAS Enterprise Guide 7.11 (SAS Institute, Cary, NC) and
R 3.2.2 (The R Foundation, Vienna Austria) were used for
statistical analysis. Figures were created with GraphPad Prism
6.07 (GraphPad Software, Inc., La Jolla, CA).
A p-value <0.05 was considered to be statistically
signiﬁcant.
Ethical considerations
All patients received oral and written information and gave
written consent before inclusion. The study was approved by
the Scientiﬁc Ethics Committee of The Capital Region of
Denmark (protocol number H-4–2013-063) and complied
with the Declaration of Helsinki.
Results
Two hundred patients were included at their ﬁrst visit to the
DOC, 3 patients withdrew consent and the ﬁnal study popula-
tion included 197 patients (Fig. 1). Of these, 39 patients
(19.8%) were diagnosed with the following malignant diseases:
11 patients were diagnosed with lung cancer, 8 with colorectal
cancer, 4 with prostate cancer, 2 with breast cancer, 2 with
B-cell lymphoma and 12 with other malignant diagnoses.
During 12-month follow-up, none of the remaining 158
patients were subsequently diagnosed with cancer; 57 of these
patients had no abnormalities detected, while 101 were diag-
nosed with other nonmalignant diseases, including infections
(n5 9), endocrinologic- (n5 8), gastrointestinal- (n5 28),
cardiovascular- (n5 6), hepatologic- (n5 8), pulmonary-
(n5 7), inﬂammatory- (n5 12) and other disorders (n5 23).
Patient characteristics are presented in Table 1.
Patients in the group diagnosed with cancer were signiﬁ-
cantly older and had a higher burden of comorbidities and
previous cancer diagnoses compared to the group with no
cancer at follow-up (Table 1). A total of 135 patients
reported a weight loss at their ﬁrst consultation, and out of
these, 25 (18.5%, p5 0.53) were diagnosed with cancer. Mean
self-reported weight loss was not signiﬁcantly different
between the groups. Among standard biomarkers, albumin
and hemoglobin were lower among the cancer patients, while
CRP and ESR were elevated compared to patients without
Figure 1. Flow-chart for the study population.
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Table 1. Patient characteristics for the total patient population, patients without a final diagnosis of cancer and patients with a final diagnosis of cancer
No cancer p Values
Total All No abnormality detected Nonmalignant disease Cancer vs. All vs. NAD vs. NMD
n (%) 197 (100) 158 (80.2) 57 (28.9) 101 (51.3) 39 (19.8)
Sex, n (%)
Female 101 (51.3) 85 (84.2) 34 (33.6) 51 (50.5) 16 (15.8)
Male 96 (48.7) 73 (76.0) 23 (24.0) 50 (52.1) 23 (24.0) 0.21 0.10 0.35
Age, mean6SD 62.7614.0 60.9614.4 57.0615.3 63.2613.4 69.769.9 <0.0001 <0.0001 0.002
Weight loss (kg),
mean6SD
6.866.0
(n5177)
6.766.0 6.766.0
(n552)
6.766.0
(n594)
7.466.1
(n 531)
0.58 0.63 0.60
Previous cancer, n (%)
No 181 (91.9) 149 (82.3) 53 (29.3) 96 (53.0) 32 (17.7)
Yes 16 (8.1) 9 (56.3) 4 (25.0) 5 (31.3) 7 (43.8) 0.02 0.11 0.04
Charlson score, n (%)
Charlson score 0–1 157 (79.7) 131 (83.4) 50 (31.9) 81 (51.6) 26 (16.6)
Charlson score >1 40 (20.3) 27 (67.5) 7 (17.5) 20 (50.0) 13 (32.5) 0.04 0.02 0.12
Biochemistry, median (IQR)
Standard biomarkers
Albumin (g/L) 38 (34–41) (n5196) 38 (34–41) 40 (35–42) (n556) 38 (34–41) 35 (31-38) (n539) 0.003 0.0005 0.02
CRP (mg/L) 3 (1–11) (n5179) 2 (1–7) 1 (1–4) (n547) 3 (1–9) (n595) 11 (6-39) (n537) <0.0001 <0.0001 <0.0001
Hemoglobin (mmol/L) 8.3 (7.5–8.9) 8.4 (7.8–9.0) 8.5 (7.8–9.1) 8.4 (7.8–8.9) 7.5 (6.5-8.6) 0.001 0.002 0.005
LDH (IU/L) 164 (145–196) (n5195) 162 (146–194) 157 (142–173) (n556) 167 (148–197) (n5100) 173 (143-211) 0.25 0.08 0.53
WBC count (109/L) 7.7 (6.4–9.0) 7.6 (6.2–8.8) 7.5 (6.1–9.0) 7.6 (6.6–8.8) 8.3 (6.5-9.4) 0.05 0.05 0.11
ESR (mm) 12 (5–23) (n5191) 9 (5–20) 7 (3–13) (n556) 12 (5–22) (n598) 23 (16-39) (n537) <0.0001 <0.0001 0.001
Immunological biomarkers
suPAR (ng/mL) 3.1 (2.3–4.6) (n5190) 2.9 (2.2–4.2) 2.5 (2.0–3.1) (n555) 3.5 (2.5–4.6) (n597) 4.7 (3.1-6.8) (n538) <0.0001 <0.0001 0.003
Ficolin-1 (ng/mL) 191.8 (80.4–295.9)
(n5185)
195.0 (81.3–287.6) 132.5 (60.0–270.9)
(n553)
197.1 (87.3–287.6)
(n593)
179.0 (75.4-411.0) 0.62 0.22 0.98
Ficolin-2 (mg/mL) 5.0 (3.1–7.4) (n5184) 4.8 (2.9–7.0) 5.3 (3.5–7.3) (n553) 4.3 (2.6–6.9) (n592) 5.2 (3.8-8.2) 0.20 0.78 0.09
Ficolin-3 (mg/mL) 24.7 (10.8–40.0) (n5185) 25.0 (11.7–40.2) 24.2 (11.5–34.8) (n553) 28.2 (12.6–44.0) (n593) 21.8 (7.9-34.5) 0.31 0.83 0.17
MBL (mg/mL) 1.99 (0.79–5.78) (n5185) 2.08 (0.83–5.88) 2.08 (1.15–5.49) (n553) 2.07 (0.72–6.31) (n593) 1.89 (0.57-5.70) 0.59 0.60 0.65
Pentraxin-3 (ng/mL) 2.9 (1.5–5.2) (n5185) 2.8 (1.5–5.1) 1.9 (1.5–4.2) (n553) 2.9 (1.5–5.2) (n593) 3.9 (2.7-6.1) 0.05 0.01 0.18
n is added in parentheses for variables with missing values.
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LDH, lactate dehydrogenase; MBL, mannose-binding lectin; NAD, no abnormality detected; NMD, nonmalignant disease;
SD, standard deviation; suPAR, soluble urokinase plasminogen activator receptor; WBC, white blood cell.
Tumor Markers and Signatures
cancer, patients with no abnormalities detected as well as
patients with other nonmalignant diseases (Table 1). There
was a borderline signiﬁcant increase in white blood cell count
among cancer patients (Table 1).
Patients with cancer had signiﬁcantly higher suPAR and
there was a borderline signiﬁcant increase in pentraxin-3
compared to cancer-free patients, but none of the other PRRs
were signiﬁcantly different between the two groups (Table 1).
The group of patients who had no abnormalities detected
had markedly lower levels of CRP, ESR, suPAR and
pentraxin-3, whereas albumin and hemoglobin was higher
compared to patients diagnosed with cancer (Table 1).
Patients diagnosed with other nonmalignant diseases had bio-
marker levels between that of cancer patients and patients
with no abnormalities detected (Table 1).
Compared to the patients who had no abnormalities
detected, the 12 patients with inﬂammatory disorders had
signiﬁcantly lower median (IQR) albumin [32 g/L (30–38),
p5 0.004] and hemoglobin [7.8 mmol/L (7.0–8.4), p5 0.03]
levels, and signiﬁcantly higher median (IQR) CRP [11.5 mg/L
(4.0–51.5), p< 0.001], ESR [21 mm (10–67), p5 0.0008] and
suPAR [4.2 ng/mL (3.4–5.3), p5 0.008]. In addition, there
was a trend toward increased ﬁcolin-1 [244.7 ng/mL (146.9–
454.4), p5 0.06] and pentraxin-3 [5.1 ng/mL (2.8–6.8),
p5 0.07] levels in these patients.
In univariate logistic regression analyses, age, previous cancer,
Charlson score, lactate dehydrogenase, hemoglobin, white blood
cell count, CRP, ESR and suPAR were signiﬁcantly associated
with newly diagnosed cancer during follow-up (Table 2).
When adjusted for both age and sex, the following
remained signiﬁcantly associated with newly diagnosed can-
cer during follow-up: age, previous cancer, hemoglobin, white
blood cell count, CRP, ESR and suPAR (Table 2). None of
the soluble PRRs investigated were signiﬁcantly associated
with cancer diagnoses (Table 2).
When CRP was included in the adjusted analysis along
with age and sex, only previous cancer, suPAR and CRP itself
remained signiﬁcantly associated with newly diagnosed can-
cer (Table 2).
To investigate the relationship between the three inﬂam-
matory biomarkers CRP, ESR and suPAR, we performed
pairwise correlation analyses (Fig. 2). There was a strong pos-
itive correlation between CRP and ESR, and suPAR was also
positively correlated with both CRP and ESR but to a lesser
degree.
For the variables that remained signiﬁcantly associated with
incident cancer after adjustment for age and sex, we performed
ROC curve analyses which resulted in the following AUCs
(95% CI): age 0.675 (0.592–0.757), previous cancer 0.561
(0.498–0.625), hemoglobin 0.670 (0.565–0.775), white blood
cell count 0.600 (0.496–0.704), CRP 0.761 (0.676–0.845), ESR
0.719 (0.627–0.810) and suPAR 0.721 (0.632–0.810).
Furthermore, to compare the predictive values of CRP
and suPAR, we performed ROC curve and logistic regression
Table 2. Associations between potential risk factors and cancer
Univariate Adjusted for age and sex Adjusted for age, sex and CRP
Variable OR (95% CI) p OR (95% CI) p OR (95% CI) p
Sex (male) 1.67 (0.82–3.41) 0.16 1.83 (0.87–3.82) 0.11 1.57 (0.70–3.53) 0.27
Age (per year) 1.05 (1.02–1.08) 0.0007 1.05 (1.02–1.09) 0.0006 1.03 (1.00–1.07) 0.06
Weight loss (per 5 kg) 0.92 (0.63–1.33) 0.65 0.90 (0.62–1.30) 0.57 0.92 (0.60–1.39) 0.69
Previous cancer 3.62 (1.26–10.44) 0.02 3.57 (1.14–11.23) 0.03 9.27 (2.20–39.01) 0.002
Charlson score 1.49 (1.08–2.05) 0.01 1.29 (0.93–1.81) 0.13 1.26 (0.88–1.78) 0.20
Albumin (log2) 0.92 (0.41–2.03) 0.83 1.46 (0.50–4.27) 0.49 2.60 (0.77–8.76) 0.12
LDH (log2) 2.04 (1.05–3.98) 0.04 1.71 (0.86–3.40) 0.13 1.46 (0.73–2.95) 0.29
Hemoglobin (log1.1) 0.64 (0.51–0.81) 0.0003 0.70 (0.54–0.90) 0.006 0.82 (0.62–1.08) 0.15
White blood cell count 1.18 (1.03–1.36) 0.02 1.18 (1.01–1.36) 0.03 1.11 (0.97–1.28) 0.14
CRP (log2) 1.50 (1.26–1.79) <0.0001 1.41 (1.18–1.70) 0.0002 1.41 (1.18–1.70) 0.0002
ESR (log2) 1.62 (1.26–2.09) 0.0002 1.44 (1.10–1.89) 0.007 1.06 (0.76–1.46) 0.75
suPAR (log2) 3.36 (1.91–5.93) <0.0001 2.58 (1.41–4.71) 0.002 2.33 (1.19–4.58) 0.01
Ficolin-1 (log2) 1.04 (0.82–1.32) 0.74 1.00 (0.77–1.28) 0.97 0.84 (0.64–1.11) 0.22
Ficolin-2 (log2) 1.34 (0.88–2.03) 0.17 1.40 (0.91–2.16) 0.13 1.25 (0.78–2.02) 0.36
Ficolin-3 (log2) 0.92 (0.71–1.17) 0.48 0.95 (0.73–1.23) 0.69 0.90 (0.67–1.19) 0.45
MBL (log2) 0.95 (0.77–1.16) 0.60 0.98 (0.79–1.21) 0.84 0.95 (0.75–1.19) 0.63
Pentraxin-3 (log2) 1.18 (0.89–1.55) 0.24 1.16 (0.85–1.58) 0.36 0.99 (0.68–1.43) 0.94
Abbreviations: CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; MBL,
mannose-binding lectin; suPAR, soluble urokinase plasminogen activator receptor.
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analyses for a full model containing age, sex, previous cancer,
CRP and suPAR and compared it with a model without CRP
and a model without suPAR, respectively (Table 3). Combin-
ing both CRP and suPAR gave the highest AUC, sensitivity
and an NPV of 93.4% (Table 3).
Discussion
In the present study, we evaluated known and novel bio-
markers for their association with cancer. We found that
hemoglobin, white blood cell count, CRP, ESR and the bio-
marker suPAR as well as previous cancer were associated
with incident cancer after adjustment for both age and sex.
When CRP was included in the adjusted analyses, only previ-
ous cancer, CRP and suPAR remained signiﬁcantly associated
with cancer; patients with previous cancer had the highest
risk, and the AUC, sensitivity and NPV were improved when
using CRP and suPAR together in the full model.
Fast diagnosis and subsequent initiation of correct treat-
ment is vital for the overall prognosis in patients diagnosed
with cancer.35–37 Prolonging the diagnostic time interval
increases the risk of a more advanced stage of the cancer at the
time of diagnosis,37 and survival is decreased with increasing
stage of the disease at diagnosis.36 Therefore, it is equally
important to successfully and rapidly detect and diagnose can-
cers and not end the diagnostic process prematurely in patients
who suffer from unrecognized serious diseases.
NSSC patients in fast-track DOCs pose a diagnostic chal-
lenge as they represent a heterogeneous group that suffer
from a wide range of conditions, ranging from various can-
cers to infections, autoimmune diseases and healthy individu-
als.2 Developing a diagnostic strategy that covers a broad
variety of conditions is thus needed. A variety of biomarkers
might help in screening and early detection of cancer6 but
many have not been evaluated in clinical use.
Although the biomarkers that were signiﬁcantly associated
with incident cancer trended toward abnormal values in
patients with cancer, the median levels were virtually within
the normal reference ranges, complicating clinical decision
making. However, patients with no abnormalities detected
had low CRP and suPAR levels—which were comparable to
that of healthy people in the general population, including
blood donors38–40—while patients receiving a diagnosis had
increased CRP and suPAR levels, especially patients with
incident cancer. Both CRP and suPAR contributed to an
improved negative predictive value.
CRP, ESR and the novel inﬂammatory biomarker suPAR
were all positively correlated with each other, with the stron-
gest correlation found between CRP and ESR, consistent with
previous research.41 suPAR showed a weaker correlation with
CRP and ESR, possibly because the biomarkers reﬂect differ-
ent aspects of inﬂammation,42 but, more likely, the difference
between suPAR and the other inﬂammatory biomarkers
could be due to the high expression of uPAR on cancer cells
and surrounding stromal cells,18–20 causing the increase in
suPAR levels.
To our knowledge, this is the ﬁrst study investigating the
association between MBL, ﬁcolin-1–3 and pentraxin-3 with inci-
dent cancer in a group of NSSC patients. Several studies have
previously found an association between increased levels of these
biomarkers and various organ-speciﬁc cancers.7,8,10,12–15 For
Figure 2. Pairwise correlations between C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR) and soluble urokinase
plasminogen activator receptor (suPAR) with Kendall’s Tau-b
correlation coefficient and linear regression line. Note the
logarithmic axes.
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example, pentraxin-3 levels have been found to be associated
with lung cancer,7 gliomas8,9 and prostate cancer,10 and high
pentraxin-3 expression was found to be associated with poor sur-
vival in lung cancer.7,43 Similarly, ﬁcolin-1 (M-ﬁcolin) has been
associated with colorectal cancer,12 and serum concentrations of
ﬁcolin-2 (L-ﬁcolin) and ﬁcolin-3 (H-ﬁcolin) have been found to
be increased in patients with malignant ovarian tumors com-
pared to benign tumors or normal ovaries.13,14 Also, MBL con-
centration has been found to be increased in patients with
colorectal cancer,15 advanced ovarian cancer,16 glioblastoma
multiforme17 and thyroid cancer.11
On the contrary, serum and intrahepatic ﬁcolin-2 levels
have also been found to be decreased in patients with hepato-
cellular carcinoma compared to healthy persons,44 and in
children with cancer, serum ﬁcolin-1 levels were not different
from age-matched controls.45 In our patient cohort, these
PRRs did not add diagnostic information; pentraxin-3 was
signiﬁcantly higher in patients with cancer compared to
patients with no abnormalities detected, but this association
was not signiﬁcant in the adjusted analyses. Even though
these biomarkers are not relevant in cancer diagnostics for
NSSC patients, they could still be useful in selected cancer
cohorts. For the patients with inﬂammatory disorders, we
observed a trend toward increased ﬁcolin-1 and pentraxin-3
compared to patients with no abnormalities detected, sugges-
ting that these PRRs are associated with inﬂammatory dis-
ease. This is supported by a systematic review and meta-
analysis of 20 studies, where serum and plasma levels of
pentraxin-3 were found to be elevated in autoimmune and
inﬂammatory disorders compared to normal controls.46 Simi-
larly, plasma ﬁcolin-1 has been found to be associated with
rheumatoid arthritis,47 but no signiﬁcant difference was
observed in ﬁcolin-1 levels between systemic lupus erythema-
tosus patients and healthy controls.48
Regarding the medical history factors examined, the
Charlson comorbidity score showed a moderate association
with cancer in NSSC patients, but this disappeared in the
multivariate models.
Conﬂicting results exist concerning an association between
involuntary weight loss and cancer for patients with
nonspeciﬁc symptoms.49,50 Interestingly, involuntary weight
loss is often the major cause of concern of cancer and referral
to the DOC, but it was not associated with incident cancer in
our study. As weight loss in this study was self-reported it
may be subject to recall bias. Similar to previous ﬁndings,
cancer was only diagnosed in 18.5% of the patients who
reported a weight loss.1
As a fast-track cancer pathway for NSSC patients, the pur-
pose of the DOCs is to uncover hidden malignancy as well as
exclude other present serious disease with a high degree of
certainty. Discovery of a single or a collection of biomarkers
that can rule out cancer with high speciﬁcity would be an
invaluable addition to both cancer screening in the general
population as well as in evaluation of patients with NSSC.
The biomarker suPAR was shown to add signiﬁcant and
independent value to diagnosing cancer among patients with
NSSC. Thus, combining suPAR with other independent fac-
tors may improve diagnostic efﬁcacy. Interestingly, suPAR
has previously been shown to carry prognostic value in can-
cer patients27,51 and may as such add to both diagnosing and
prognosticating cancer patients and accordingly uPAR is cur-
rently pursued as a promising imaging and radiotherapeutic
target.52–55 In any case, the positive and negative predictive
values must be examined in a larger patient cohort to estab-
lish a clinical cutoff, and combining high sensitivity bio-
markers with high speciﬁcity biomarkers to detect cancer6 or
constructing a predictive model consisting of biomarkers and
clinical information would also require development and vali-
dation in cohorts larger than the present.
Strength and limitations
The examined cohort is small with few cases of cancers and
therefore has character of a pilot study. As mentioned, weight
loss was self-reported and may be subject to recall bias. Fur-
thermore, the patients have a high degree of comorbidity and
competing illnesses which makes the data more difﬁcult to
interpret, but this also strengthens the study as this patient
sample is highly representative of the entire population of
NSSC patients, making the results from this prospective study
applicable in clinical practice. A larger patient cohort is also
Table 3. Logistic regression and ROC curve analysis
AUC (95% CI) p
Sensitivity
(95% CI) Specificity (95% CI) NPV (95% CI) PPV (95% CI)
Age, sex, previous
cancer,
CRP, suPAR
0.802 (0.723–0.881) 0.021 0.806 (0.676–0.935) 0.728 (0.653–0.803) 0.934 (0.887–0.981) 0.439 (0.320–0.559)
Age, sex, previous
cancer, CRP
0.759 (0.669–0.848) 0.072 0.722 (0.576–0.869) 0.743 (0.669–0.816) 0.910 (0.857–0.963) 0.426 (0.302–0.550)
Age, sex, previous
cancer, suPAR
0.776 (0.691–0.862) 0.132 0.694 (0.544–0.845) 0.787 (0.718–0.856) 0.907 (0.854–0.959) 0.463 (0.330–0.596)
1Comparison of all three ROC curves, 2 degrees of freedom.
2Pairwise difference, compared to the full model, 1 degree of freedom.
Abbreviations: AUC, area under the curve; CI, confidence interval; CRP, C-reactive protein; NPV, negative predictive value; PPV, positive predictive
value; suPAR, soluble urokinase plasminogen activator receptor.
T
u
m
o
r
M
ar
k
er
s
an
d
S
ig
n
at
u
re
s
Rasmussen et al. 197
Int. J. Cancer: 141, 191–199 (2017) VC 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
Union for International Cancer Control
needed to establish how these biomarkers relate to other seri-
ous nonmalignant diagnoses.
Conclusion
In this study, previous cancer, CRP and suPAR were signiﬁ-
cantly associated with cancer diagnosis in patients with non-
speciﬁc signs and symptoms. The PRRs ﬁcolin-1–3, MBL and
pentraxin-3 were not associated with cancer.
To examine the optimal screening strategy using
biomarkers to identify cancer, more studies are required. The
inﬂammatory biomarker suPAR is a promising new bio-
marker in the DOC setting, but the predictive values of
suPAR in patients with NSSC should be examined in a larger
patient material.
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